Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- Breast Cancer Risk Genes
- Genes Associated With Breast Cancer
- Palbociclib With Adjuvant Endocrine Therapy in Early Breast Cancer
- Real-World Outcomes Among Patients With Metastatic Triple-Negative Breast Cancer
- Fixed-Dose Combined Pertuzumab/Trastuzumab for Subcutaneous Injection Plus Chemotherapy in HER2+ Early Breast Cancer
- Omission of Chemotherapy Among Node-Positive Patients With ER+ Breast Cancer
- Serial ctDNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
- Serial ctDNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
- Eflapegrastim for Prevention of Chemotherapy-Related Neutropenia Among Patients With Early Stage Breast Cancer